Viewing data from:

PREVALITE

ANDA

CHOLESTYRAMINE | A073263 | AIPING PHARMACEUTICAL INC

2 strengths0 unique patents0 unique exclusivities

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-08-26 | 3 NDCs

Highest NADAC/Unit

$0.8034

per ea

Lowest NADAC/Unit

$0.1621

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
00245003642PREVALITE PACKET	$0.8034	EA	Generic	—	2026-08-19
00245003660PREVALITE PACKET	$0.8034	EA	Generic	—	2026-08-19
00245003623PREVALITE POWDER	$0.1621	GM	Generic	—	2026-08-19

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 1 NDC (1 FSS)

Lowest Price

$26.09

Highest Price

$26.09

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
00245-0036-42PREVALITE	$26.09	FSS	Upsher-Smith Laboratories, LLC	04/30/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data across 2 drug listings matched to this application (2023)

Prevalite — Cholestyramine/Aspartame (2023)

Total Spending

$6.7M

Total Claims

54,881

Beneficiaries

23,744

Avg Cost/Unit

$1.40

Spending Trend

$11.7M(2019)→$10.9M(2020)→$10.9M(2021)→$10.1M(2022)→$6.7M(2023)

YoY Change:-4.5%

5yr CAGR:-4.6%

Prevalite — Cholestyramine (2024)

Total Spending

$4.5M

Total Claims

42,666

Beneficiaries

18,851

Avg Cost/Unit

$1.10

Spending Trend

$10.9M(2020)→$10.9M(2021)→$10.1M(2022)→$6.7M(2023)→$4.5M(2024)

YoY Change:-21.1%

5yr CAGR:-9.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs2 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

PUROLITE LLCCHOLESTYRAMINE RESIN USP

DMF 73241988

ION EXCHANGE INDIA LTDCHOLESTYRAMINE RESIN USP (INDION 454)

DMF 231712009

PHAEX POLYMERS PRIVATE LTDCHOLESTYRAMINE RESIN USP AS IN

DMF 276072013

DOW CHEMICAL COInactiveCHOLESTYRAMINE USP

DMF 57591985

ROHM AND HAAS COInactiveCHOLESTYRAMINE RESIN, USP-AMBERLITE IRP-276

DMF 65061986

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (2)

Sort:

#001 — EQ 4GM RESIN/PACKET

0 patents0 exclusivities▴

POWDER;ORAL | Approved: Feb 22, 1996

No patent or exclusivity listings for this strength.

#002 — EQ 4GM RESIN/SCOOPFUL

0 patents0 exclusivities▾

POWDER;ORAL | Approved: Oct 30, 1997